KEGG   DRUG: Prademagene zamikeracel
Entry
D13121                      Drug                                   
Name
Prademagene zamikeracel (INN);
Zevaskyn (TN)
Product
ZEVASKYN (Abeona Therapeutics)
Remark
Product: D13121<US>
Efficacy
Wound healing, Functionnal collagene synthesis promoter
  Disease
Wounds with recessive dystrophic epidermolysis bullosa [DS:H00587]
  Type
Cellular therapy product
Comment
Genetically modified cell, human culture expanded genetically modified autologous keratinocytes for cell-based gene therapy
Target
COL7A1 [HSA:1294] [KO:K16628]
  Pathway
hsa04974  Protein digestion and absorption
Brite
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Organismal systems
   Digestive system
    COL7A1
     D13121  Prademagene zamikeracel (INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D13121
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D13121
Other DBs
PubChem: 513131725
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system